High-Field MRI-Guided Linear Accelerator Brings Together Imaging, Radiotherapy to Zap Tumors

UMCU MRLINAC installation High Field MRI Guided Linear Accelerator Brings Together Imaging, Radiotherapy to Zap Tumors

Radiation therapy using linear particle accelerators can be a bit a hit or miss process, since imaging of tumors and the therapy are done separately. A new system being installed at University Medical Center Utrecht in The Netherlands aims to bring together magnetic resonance imaging and a linear accelerator.

high field High Field MRI Guided Linear Accelerator Brings Together Imaging, Radiotherapy to Zap Tumors

Philips is supplying a 1.5 T MRI that will work with an Elekta linear accelerator. The project is actually led by a consortium of Dutch, American, and Canadian clinical centers.

More from a Philips announcement:

In the coming months, additional components will be integrated and the system will undergo a program of non-clinical testing, which includes the performance evaluation of MRI sequences, testing of different adaptive delivery methods, establishing quality assurance techniques and defining workflow.

“Since formation of the consortium in 2012, members have been exploring the feasibility of high-field MRI-guided radiotherapy. Installation of the first generation system is truly a major step toward moving this technology into the clinic to benefit patients,” says Bas Raaymakers, PhD, Associate Professor, Department of Radiotherapy, UMC Utrecht. “We’re immensely proud of the critical role that UMC Utrecht has played in collaboration with Philips and Elekta in this project for over 10 years.”

“As the founding member of the consortium, UMC Utrecht has been instrumental in turning the concept of MRI guided radiation therapy into a working system, and has invested a great deal of effort and resources to make it a reality,” adds Tomas Puusepp, President and CEO, Elekta. “We are excited about the prospect of taking high-field MRI-guided radiation therapy to the next stage.”

“Highly targeted treatments will be essential in the battle to control cancer, so together with our partners we are stepping up our efforts to create new solutions in interventional oncology,” says Gene Saragnese, CEO Imaging Systems at Philips Healthcare. “The installation of the first generation MR-guided radiation system at UMC Utrecht is an important milestone in the development of an innovation that is designed to make a real difference in cancer care.”

In addition to UMC Utrecht, the other consortium members are: The University of Texas MD Anderson Cancer Center (Houston, Texas), The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (Amsterdam, the Netherlands), Sunnybrook Health Sciences Centre (Toronto, Ontario) and The Froedtert & Medical College of Wisconsin Cancer Center (Milwaukee, Wisconsin).

Press release: Dutch medical center begins installation of world’s first high-field MRI-guided radiation therapy system….

Sumitomo Receives FDA Approval for Company’s Proton Therapy System

Sumitomo Receives FDA Approval for Company's Proton Therapy System

Sumitomo Heavy Industries, a Japanese conglomerate, has received FDA clearance for its Proton Therapy System. Sumitomo was one of the world’s first manufacturers of proton therapy systems, with its first commercial system having been released already in 1997 in Japan.

The current system has a 230MeV proton accelerator (cyclotron) and 360 degree single or multiple rotating gantries. The proton beams can reach up to a 32cm depth into the body and a rotational gantry can help irradiate at any angle and is compatible for use with respiratory gating. Also, a fixed beam room is provided with the system for treatment of head and neck tumors.

Read More »

Protura Robotic Patient Positioning System Cleared to Interface with Varian’s Accelerometers

Protura Robotic Patient Positioning System Cleared to Interface with Varian's Accelerometers

CIVCO (Kalona, Iowa) won FDA clearance for the integration of its Protura Robotic Patient Positioning System with Varian‘s Clinac iX and Trilogy linear accelerators. The system features sub-millimeter accuracy and six degrees of freedom of movement, and is controlled by its own software that downloads data from Varian’s 4DTC System through the Motion Management Interface to ensure accuracy of positioning during image guided radiation therapy.

Read More »

Pinnacle3 Proton Therapy System Wins FDA Clearance for Treatment Planning

Pinnacle3 Proton Therapy System Wins FDA Clearance for Treatment Planning

Philips has announced that the FDA has approved its Pinnacle3 Proton module that was developed to plan proton therapy treatment sessions. Proton therapy is becoming more common even though it is very expensive, but the promise of safer, more effective treatment has continued to promote its development.

The Proton module works within the company’s Pinnacle3 system, together providing for planning of treatment using either proton or photon (gamma, etc) modalities independently, or as a combination of the two. The software works with a number of proton therapy systems, so can be purchased independently of the hardware installation.

Read More »

Elekta Unveils More Powerful and Precise Versa HD Radiotherapy System (w/video)

Elekta Unveils More Powerful and Precise Versa HD Radiotherapy System (w/video)

Elekta released the new Versa HD radiotherapy linear accelerator that features new cone beam shaping technology that delivers higher precision targeting than previous systems while achieving a large field-of-view.

It’s built around the  company’s new Agility 160-leaf multileaf collimator, delivering much larger radiation doses and allowing for treatment of small and large targets without compromising the sharpness of the beam.

Read More »

Gold Coated Nanoparticles Created to Ferry Alpha Radiation Sources to Tumors (w/video)

Gold Coated Nanoparticles Created to Ferry Alpha Radiation Sources to Tumors (w/video)

Cancer therapy that involves injecting radioactive particles into tumor sites is a tried but not quite true method. One problem is delivering sufficient energy to diseased tissue without hurting the rest of the body too much. This is why radiopharmaceuticals that emit beta radiation (electrons) have been used. Alpha radiation emitting (2 protons + 2 neutrons) radionuclides have such comparatively enormous energy that they need to be carefully contained so as to not cause more harm than good, which has been difficult to accomplish.

Now researchers from University of Missouri and Oak Ridge National Laboratory are reporting the development of gold coated lanthanide phosphate nanoparticles that effectively contain actinium, an alpha decaying element. These nanoparticles can be injected to tumor sites with much more confidence that the energy of the radioactive cores will be delivered to target.

Read More »

Augmenix Injectable Marker Visible Under CT, MRI, US – and Cleared in U.S.

Augmenix Injectable Marker Visible Under CT, MRI, US - and Cleared in U.S.

Augmenix (Waltham, MA) received FDA clearance for its hydrogel injectable TraceIT Tissue Marker. This marker is useful because it’s visible under CT, MRI, cone beam CT, and ultrasound. The first of its kind, the marker remains stable (but harmless) and visible for at least three months after which time it is resorbed and excreted by the body.

The new marker will help clinicians more confidently fuse MRI and CT images, and make cone beam CT more useful during radiotherapy.

Read More »

Varian EDGE Radiosurgery System With Advanced Motion Correction Cleared in U.S.

Varian EDGE Radiosurgery System With Advanced Motion Correction Cleared in U.S.

Varian Medical Systems won FDA approval for its new EDGE radiosurgery system that was unveiled only four months ago. The stereotactic system uses real time tumor and motion tracking to precisely attack tumors and lesions throughout the body, including lungs and and brain.

Varian is still awaiting FDA clearance for the Calypso anchored Beacon transponders that are implanted within the lungs and used along with the EDGE system to precisely attack lung tumors.

Read More »

Lantheus Announces First Technetium-99m Isotope Generator from Low Enriched Uranium

Lantheus Announces First Technetium-99m Isotope Generator from Low Enriched Uranium

Last week the American Medical Isotopes Production Act of 2011 (AMIPA) finally became law, and America is planning on curtailing the use and export of highly enriched uranium (HEU) for the production of medical isotopes.

Coinciding with President Obama’s signing of the act into law, Lantheus Medical Imaging, Inc. of N. Billerica, MA, is now making available its LEU TechneLite generator, the first technetium-99m (Tc-99m) generator in the US that uses molybdenum-99 (Mo-99) sourced from at least 95% low enriched uranium.

Read More »